Sublingual buprenorphine in acute pain management: a double-blind randomized clinical trial

Ann Emerg Med. 2012 Apr;59(4):276-80. doi: 10.1016/j.annemergmed.2011.10.021. Epub 2011 Nov 23.

Abstract

Study objective: We compare the efficacy and safety of sublingual buprenorphine versus intravenous morphine sulfate in emergency department adults with acute bone fracture.

Methods: Enrolled patients received buprenorphine 0.4 mg sublingually or morphine 5 mg intravenously in this double-blind, double-dummy, randomized controlled trial. Patients graded their pain with a standard 11-point numeric rating scale before medication administration and 30 and 60 minutes after, and we recorded adverse reactions.

Results: We analyzed 44 and 45 patients in the buprenorphine and morphine groups, respectively. Mean pain scores were similar at 30 minutes (5.0 versus 5.0; difference 0; 95% confidence interval -0.6 to 0.8) and at 60 minutes (2.2 versus 2.2; difference 0; 95% confidence interval -0.3 to 0.3). Adverse effects observed within 30 minutes were nausea (14% versus 12%), dizziness (14% versus 22%), and hypotension (4% versus 18%).

Conclusion: For adults with acute fractures, buprenorphine 0.4 mg sublingually is as effective and safe as morphine 5 mg intravenously.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Sublingual
  • Adult
  • Analgesics, Opioid* / administration & dosage
  • Buprenorphine* / administration & dosage
  • Double-Blind Method
  • Emergency Service, Hospital
  • Female
  • Fractures, Bone*
  • Humans
  • Injections, Intravenous
  • Male
  • Morphine / administration & dosage
  • Pain Management / methods*
  • Pain Measurement
  • Time Factors

Substances

  • Analgesics, Opioid
  • Buprenorphine
  • Morphine